文献速递胃肠外科围术期管理与 ERAS

经肛全直肠系膜切除术的长期肿瘤学结局:单中心至少5年随访队列

Long-term oncologic outcomes after transanal total mesorectal excision: a single-center cohort with a minimum of 5-year follow-up.
PubMed 文献 · Surg Endosc · 2026-08-27

本研究基于前瞻性维护的TaTME数据库,纳入至少随访5年的220例患者,评估局部复发、远处复发、总生存和无病生存。5年局部复发率为4.55%,远处复发率为15.94%;吻合口漏是局部复发的唯一预测因素,病理阳性淋巴结状态和吻合口漏是远处复发的显著预测因素。

要点

  • TaTME术后5年局部复发率4.55%,远处复发率15.94%。
  • 吻合口漏是局部复发的唯一预测因素(SHR 4.01,P=0.012)。
  • 病理阳性淋巴结状态和吻合口漏是远处复发的显著预测因素。

核心结论

  • TaTME术后观察到可接受的肿瘤学和生存结局。
  • 吻合口漏是疾病复发的最强预测因素,强调精细手术技术和优化围术期管理对改善长期肿瘤学结局的重要性。

研究设计与样本

  • 基于前瞻性维护的TaTME数据库的单中心队列研究。
  • 仅纳入至少随访5年的患者,共220例(男性160例)。
  • 主要终点为局部复发、远处复发、总生存和无病生存;采用反向Kaplan-Meier法计算随访时间,采用累积发生率函数计算局部复发和远处复发概率(考虑竞争风险),计算亚分布风险比评估关联。

主要发现

  • 分析时60.91%患者存活,58.6%存活且无病。
  • 5年局部复发率为4.55%,远处复发率为15.94%。
  • 吻合口漏是局部复发的唯一预测因素(SHR:4.01,P=0.012)。
  • 病理阳性淋巴结状态(SHR:3.58,P=0.001)和吻合口漏(SHR:3.91,P=0.008)是远处复发的显著预测因素。

临床怎么用

  • TaTME术后应重视吻合口漏的预防和及时处理,以降低复发风险。
  • 对于病理阳性淋巴结状态的患者,需加强术后随访和复发监测。

局限性

  • 单中心回顾性队列设计可能限制结论的外推性。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transanal total mesorectal excision (TaTME) has gained increasing popularity for low to mid rectal cancer. Several studies have reported on short-term oncological outcomes and safety of this procedure, however, data regarding long-term outcomes are sparse. We aimed to evaluate the long-term oncologic and survival outcomes of patients who underwent TaTME at our center. METHODS: This study is based on our prospectively maintained TaTME database. We only included patients who had a minimum follow-up of five years. The primary endpoints were incidence of local recurrence (LR), distant recurrence (DR), overall survival (OS), and disease-free survival (DFS). Secondary endpoints included pathological outcomes and postoperative complications. We used the reverse Kaplan Meier method to calculate follow-up time, and the cumulative incidence function to calculate the probability of LR and DR, accounting for competing risks and avoiding biased estimation. We calculated subdistribution hazard ratios (SHRs) to assess the association between clinically relevant patient, disease, and pathology variables and disease recurrence (LR and DR separately). RESULTS: A total of 220 patients were included (160 male patients). At the time of analysis, 60.91% were alive, and 58.6% were alive and disease free. The incidence of LR at five years was 4.55%, and the incidence of DR was 15.94%. Anastomotic leakage was the only predictor of LR (SHR: 4.01, P = 0.012), while both pathologically positive nodal status and anastomotic leakage were significant predictors of DR (SHR: 3.58, P = 0.001 and SHR: 3.91, P = 0.008, respectively). CONCLUSION: We observed acceptable oncologic and survival outcomes following TaTME. Anastomotic leakage emerged as the strongest predictor of disease recurrence, underscoring the importance of meticulous surgical technique and optimal perioperative care in improving long-term oncologic outcomes.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Ahmed M, Sami AN, Perdawood SK, et al. Long-term oncologic outcomes after transanal total mesorectal excision: a single-center cohort with a minimum of 5-year follow-up. Surg Endosc. 2026. PMID: 42661067. doi:10.1007/s00464-026-13279-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。